# Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

* Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma.
* “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states.
* No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks.

 Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, which recent data from the IIS indicates is delivering promising treatment success in early-stage cutaneous T-cell lymphoma (“CTCL”).

 Soligenix and the Cutaneous Lymphoma Foundation recently released interim results from the open-label IIS evaluating extended HyBryte(TM) therapy administered twice weekly for up to 54 weeks in patients with early-stage mycosis fungoides (https://ibn.fm/IUoEe). At the 18-week evaluation point, six out of…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-reports-strong-results-in-real-world-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-s-hybryte-tm-shows-promise-in-early-stage-ctcl-treatment/cc290a4175f12ed83f120de59cd652fe) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1m3ampg/soligenixs_hybrytetm_shows_promise_in_earlystage/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/18/fernjCtr.webp)